Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI with Concurrent Chemotherapy in Breast Cancer
NCT00278109Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2004
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and doxorubicin in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity up to 5 years. Started Jul 2004; status: completed.
02
Drugs
cyclophosphamidedoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00278109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278109.